We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Venture Life Group Plc | LSE:VLG | London | Ordinary Share | GB00BFPM8908 | ORD 0.3P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.55 | -1.42% | 38.25 | 37.50 | 39.00 | 38.25 | 38.15 | 38.25 | 11,045 | 08:00:28 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Misc Retail Stores, Nec | 43.98M | 520k | 0.0041 | 93.29 | 48.13M |
From Apr 2019 to Apr 2024
TIDMVLG
RNS Number : 4554I
Venture Life Group PLC
01 April 2020
1 April 2020
Venture Life Group plc
("Venture Life" or the "Company")
Notice of Results
Venture Life (AIM: VLG), the international consumer self-care group focused on developing, manufacturing and commercialising products for the self-care market, today announces that it will announce its preliminary results for the year ended 31 December 2019 on Thursday 9 April 2020.
For further information please contact:
Hot Features
Premium
Venture Life Group PLC +44 (0) 1344 578 004
Jerry Randall, Chief Executive Officer
Andrew Waters, Chief Financial Officer
Cenkos Securities plc (Nominated Adviser
and broker) +44 (0) 207 397 8900
Stephen Keys / Cameron MacRitchie (Corporate
Finance)
Russell Kerr / Michael Johnson (Sales)
Alma PR venturelife@almapr.com
or
+44 (0) 203 405 0208
Helena Bogle/Hilary Buchanan/Kieran
Breheny
About Venture Life ( www.venture-life.com )
Venture Life is an international consumer self-care company focused on acquiring, developing, manufacturing and commercialising products for the global self-care market. With operations in the UK, Italy and the Netherlands, the Group's product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, , medical devices for dermatology, oral care, women's intimate healthcare and proctology, and dermo-cosmetics for addressing the signs of ageing.
The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples. In the UK and the Netherlands these are supplied direct by the company, elsewhere they are supplied by the Group's international distribution partners.
Through its Development & Manufacturing business in Italy, Biokosmes, the Group also provides development and manufacturing services to companies in the OTC consumer products sector, primarily in respect of medical devices.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
NORZFLFBBZLBBBE
(END) Dow Jones Newswires
April 01, 2020 10:10 ET (14:10 GMT)
1 Year Venture Life Chart |
1 Month Venture Life Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
